Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study to track Real-World safety of new blood disorder drugs

NCT ID NCT04398628

Knowledge-focused Sponsor: American Thrombosis and Hemostasis Network Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 4 times

Summary

This study is collecting long-term safety and effectiveness data on treatments for various blood disorders, including hemophilia, sickle cell disease, and clotting disorders. It aims to enroll 3000 people of any age with these conditions. Researchers will monitor side effects, complications, and how well treatments work in everyday practice, beyond what was seen in initial drug approval studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a real-world study in which participants with congenital or acquired blood disorders will be enrolled.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants who meet the following inclusion criteria and none of the exclusion criteria are eligible for enrollment in one of the open disease-specific arms. Inclusion Criteria: 1. Any age 2. Having a congenital or acquired blood disorder; or 3. Having a bleeding phenotype as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score with an unknown diagnosis; or 4. Connective tissue disorder with bleeding tendency as indicated by an age adjusted abnormal ISTH Bleeding Assessment Tool score. 5. Eligible for a currently active disease-specific arm. 6. Concurrent enrollment in the ATHNdataset or current ATHNdataset participant. Exclusion Criteria: 1\. Does not qualify for inclusion in a currently activedisease-specific arm; participants may be eligible to enroll as future cohorts and arms are activated; 2. Unable to give informed consent or assent 3. Unwilling to perform study procedures Cohort Participant Selection Each participant is to be enrolled in the cohort for which they qualify as defined below. Hemophilia Cohort Inclusion Criteria: Participants who meet any of the following inclusion criteria are eligible for enrollment into this cohort: 1. Factor VIII or factor IX activity \<50%, without another explanation for low clotting factor other than congenital hemophilia or being a known carrier for congenital hemophilia; OR 2. Carrier for congenital hemophilia with a factor VIII \>=50% or factor IX activity \>=50% with or without a bleeding phenotype as indicated by an ISTH Bleeding Assessment Tool score of ≥4 for adult males, ≥6 for adult females, or ≥3 for children younger than 18 years OR 3. Known congenital hemophilia that have a factor level \>50% after receiving vector, OR 4. Acquired hemophilia. Exclusion Criteria: None Von Willebrand Disease Cohort Inclusion Criteria: Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1\. Meeting the definition of VWD or low VWF per most recent international guidelines Exclusion Criteria: None Congenital Platelet Disorders Cohort Inclusion Criteria: Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1. Abnormalities of platelet function a. Glanzmann thrombasthenia (GPIIb or GPIIIa) b. Bernard-Soulier syndrome (GPIbalpha, GPIbbeta, or GPIX) 2. Abnormalities of platelet granules 3. Abnormalities of platelet signal transduction 4. Abnormalities of platelet secretion 5. Collagen Receptor Defect 6. ADP Receptor Defect 7. Thromboxane Receptor Defect 8. Giant Platelet Disorder 9. Abnormalities in platelet aggregation testing due to another or unknown cause (not drug related) Exclusion Criteria: 1\. Platelet disorders secondary to medications or other substances Rare Disorders Cohort Inclusion Criteria: Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1\. Have an established Rare Coagulation Disorder (RCD) diagnosis of one of the following: 1. PAI-1 deficiency 2. Factor I, II, V, VII, X, XI, XIII deficiencies 3. Combined FV and FVIII deficiency 4. Plasminogen deficiency 5. Decreased tissue plasminogen activator 6. Afibrinogenemia/hypofibrinogenemia/dysfibrinogenemia 7. Thrombotic Thrombocytopenia Purpura or Congenital Hemolytic Uremic Syndrome 8. Wiskott-Aldrich 9. Methylenetetrahydrofolate Reductase Deficiency Exclusion Criteria: None Bleeding NOS Cohort Inclusion Criteria: Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1. Have a bleeding phenotype as indicated by an ISTH Bleeding Assessment Tool score of ≥4 for adult males, ≥6 for adult females, or ≥3 for children younger than 18 years with an unknown diagnosis, OR 2. Connective tissue disorder with bleeding tendency as indicated by an ISTH Bleeding Assessment Tool score of ≥4 for adult males, ≥6 for adult females, or ≥3 for children younger than 18 years. Exclusion Criteria: None Thrombosis/Thrombophilia Cohort Inclusion Criteria Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1\. Have a prior history of arterial or venous thrombosis. 2. Participants with a known congenital or acquired thrombophilia with or without thrombosis. a. Common congenital thrombophilias: i. Protein C deficiency ii. Protein S deficiency iii. Antithrombin deficiency iv. Factor V Leiden v. Prothrombin gene mutation b. Rare genetic factors i. Hyperhomocysteinemia c. Indeterminate genetic factors i. Elevated factor VIII ii. Elevated factor IX iii. Elevated factor XI iv. Elevated lipoprotein (a) d. Acquired thrombophilias i. Lupus anticoagulant ii. Anti-cardiolipin antibodies/Beta2 glycoprotein antibodies iii. Antiphospholipid syndrome Exclusion Criteria Acquired thrombophilia secondary to medications (birth control pills or hormone replacement therapy), overweight or obesity, smoking, cancer, pregnancy, surgery, injury, prolonged inactivity/bedrest, heart failure, inflammatory bowel disease, or kidney disease Non-Neoplastic Hematologic Conditions Cohort Inclusion Criteria Participants who meet the following inclusion criteria are eligible for enrollment into this cohort: 1\. Having any congenital or acquired non-neoplastic hematologic disorder not included in any other cohort Exclusion Criteria None Arm/Module Participant Selection Previously Untreated Patients Arm Inclusion Criteria: 1. Diagnosis of congenital hemophilia A (FVIII \<40%) or hemophilia B (FIX \<40% or below lower limit for age) 2. Age \<18 years at time of enrollment 3. Parent or authorized guardian or legally authorized representative (LAR) can provide informed consent 4. Care established at one of the ATHN Transcends participating HTCs 5. Clotting Factor Concentrate (CFC) exposure, fresh frozen plasma (FFP), cryoprecipitate, and single donor platelets \<3 exposure days (ED) Exclusion Criteria 1. Concomitant diagnosis with another bleeding disorder 2. History of a confirmed, positive inhibitor INHIBIT Module Inclusion Criteria: 1\. Diagnosis of severe factor VIII deficiency with baseline factor VIII level \<1% 2. Initiating or plan to initiate prophylaxis with emicizumab or factor replacement 3. Factor concentrate exposure, Fresh Frozen Plasma (FFP), cryoprecipitate, and single donor platelets ≤3 EDs 4. ≤5 years of age Exclusion Criteria 1. Concomitant diagnosis with bleeding disorder other than hemophilia A 2. Immune disorder 3. Previous history or presence of factor VIII inhibitor. A confirmed, positive inhibitor is defined as two consecutive positive inhibitor titers (≥ 0.6 BU) that result in changes in treatment recommendations. Efanesoctocog alfa (ALTUVIIIO®) Module Inclusion criteria: 1. Ability of the potential participant's legally authorized representative (e.g., their parent or legal guardian) to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local participant privacy regulation. 2. People with severe HA with a baseline FVIII activity of less than 1%. (While inclusion for participation in ATHN Transcends lists \<5% FVIII activity, this proposed module will limit enrollment to people with FVIII activity levels of \<1%.) Other severities may be included per ATHN Transcends PI approval. 3. \<18 years of age. 4. No history of a confirmed, positive FVIII inhibitor. 5. Sex assigned at birth of male, female, or intersex. 6. Participants should have no more than three (3) exposure days of blood products (fresh frozen plasma, cryoprecipitate, or platelets), no more than three (3) doses of any FVIII concentrate other than efanesoctocog alfa, and up to three (3) doses of efanesoctocog alfa prior to enrollment. 7. Site PI confirmed all inclusion criteria has been met. Exclusion criteria: 1. Not meeting all the inclusion criteria; confirmed by site PI. 2. Any exposure to blood products or FVIII replacement products except as described in the inclusion criteria. 3. History of positive inhibitor testing. 4. History of hypersensitivity reactions associated with efanesoctocog alfa administration. 5. Other coagulation disorder(s) in addition to Hemophilia A. 6. Any concurrent clinically significant major disease such as cancer that, in the opinion of the investigator, would make the participant unsuitable for enrollment. 7. Concurrent systemic treatment with chemotherapy and/or other immunosuppressant medications. Use of corticosteroids for the treatment of asthma or management of acute allergic or otherwise life-threatening episodes is allowed except for systemic corticosteroid treatment given to children daily or on an alternate day schedule at \> 2 mg/kg/day of prednisone or its equivalent or \> 20 mg/day if the duration is longer than 14 days. 8. Enrollment in a concurrent clinical interventional drug study. 9. Intake of an Investigational Medicinal Product within three (3) months prior to inclusion in this study. 10. Inability to comply with study requirements. 11. Other, unspecified reasons that, in the investigator's opinion, make the participant unsuitable for enrollment. Hemophilia Natural History Arm Inclusion Criteria 1. Congenital or acquired hemophilia A or B of any severity with or without inhibitors receiving a current therapy, a non-factor product, or for whom use of a non-factor product is a possibility, OR 2. Females of any age, with confirmed congenital hemophilia A or B carrier status with genetic mutational analysis and any factor level. Exclusion Criteria 1. Presence of any known bleeding disorder other than congenital hemophilia A or B 2. Presence of concurrent hemophilia and a second hemostatic defect (low von Willebrand Factor (vWF) without vWD diagnosis is not excluded) 3. Unable or unwilling to comply with the study arm protocol. Nonacog beta pegol (Rebinyn®) Module Inclusion Criteria: 1. Has provided signed written consent for the nonacog beta pegol (Rebinyn®)Module before any study-related activities. 2. Male participants, at any age with hemophilia B, naïve or minimally exposed (up to 3 EDs) to nonacog beta pegol treatment at time of study enrollment. Additional doses may be allowable per ATHN Transcends PI approval. 3. Decision to initiate continuous prophylaxis treatment with commercially available nonacog beta pegol has been made by the participant(s)/Legally Authorized Representative(s) (LAR(s)) and the treating physician before and independently from the decision to include the participant in this study. Exclusion Criteria: 1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation, including a diagnosis or suspicion of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) per the discretion of the Principal Investigator. 3. Known or suspected hypersensitivity to nonacog beta pegol or related products. 4. Clinical suspicion or presence of FIX inhibitor at time of inclusion. 5. Inability or unwillingness to undergo neurological assessment/structured developmental history. Emicizumab (Hemlibra®) Module Inclusion Criteria: 1. Participant currently treated with emicizumab (Hemlibra®) 2. Currently enrolled in the Hemophilia Natural History Arm of ATHN Transcends Exclusion Criteria: 1\. Unable or unwilling to comply with the protocol Distress Module Inclusion Criteria: 1. Congenital hemophilia A or B of any severity with or without inhibitors receiving a current therapy, a non-factor product, or for whom use of a non-factor product is a possibility 2. Age 18 years of age or older 3. English speaking Exclusion Criteria: 1. Presence of any known bleeding disorder other than congenital hemophilia A or B; 2. Presence of concurrent hemophilia and a second hemostatic defect (low von Willebrand Factor (vWF) without vWD diagnosis is not excluded); and 3. Unable or unwilling to comply with the study arm protocol Hemophilia Gene Therapy Outcomes Arm Inclusion Criteria 1. Hemophilia A or B of any severity with or without inhibitors having received or will receive a hemophilia gene transfer product in the next 6 months. 2. Age 18 years and older. 3. Able to give informed consent. Exclusion Criteria None Etranacogene dezaparvovec (HEMGENIX®) Module Inclusion Criteria: Etranacogene dezaparvovec (HEMGENIX®) Cohort 1. Age 18 years of age or older 2. Treatment with commercial etranacogene dezaparvovec (HEMGENIX®) 3. Have provided signed written informed consent within 3 months before or within 6 months after etranacogene dezaparvovec (HEMGENIX®) treatment, or within 6 months of when the study is initiated at the treating site. FIX Prophylaxis Cohort 1. Age 18 years of age or older 2. Treatment with FIX prophylaxis therapy 3. Has provided signed written consent at any time for ATHN Transcends Study Exclusion Criteria, both cohorts: 1\. Have been treated with etranacogene dezaparvovec in a clinical trial prior to commercial availability. These patients are still eligible for enrollment in the Gene Therapy Outcomes Arm, and their data may be collected for separate analysis. Congenital Platelet Disorders Arm Inclusion Criteria 1. Platelet adhesion defect 1. Bernard Soulier syndrome (Defective GPIb-IX-V receptor, impaired adhesion to vWF) 2. Velocardio-facial syndrome/DiGeorge syndrome (Defective GPIb-IX-V receptor) 3. Platelet type vWD (Defective GPIb-IX-V, gain of function interaction between vWF-GP1bα) 2. Platelet aggregation defect 1. Glanzmann thrombasthenia (Defective integrin αIIbβ3 (GPIIb/IIIa) 2. Platelet aggregation defect, NOS 3. Agonist receptor defects 1. Epinephrine 2. ADP 3. Collagen 4. Thromboxane A2 4. Platelet signaling defects 1. Cyclooxygenase deficiency (PTGS1 mutation) 2. Phospholipase A2 deficiency 3. Thromboxane synthase deficiency (TBXAS1 mutation) 4. G protein activation defect (GNAS mutation) 5. Scott syndrome (defect in phosphatidyl serine translocation) 5. Platelet Granule disorders 1. Dense granule storage pool disorder * Hermansky Pudlak syndrome * Chediak Higashi syndrome * Griscelli syndrome 2. Alpha granule storage pool disorder * Grey platelet syndrome * Arthrogryposis-Renal Dysfunction-Cholestasis (ARC) syndrome * Quebec platelet disorder * Paris-Trousseau syndrome 3. Combined alpha delta granule deficiency 6. Platelet cytoskeletal structure defects 1. Wiskott Aldrich syndrome 2. MYH9 associated disorders (myosin heavy chain) * May Hegglin syndrome * Fechtner syndrome * Sebastian syndrome * Epstein syndrome 3. Other mutations * FLNA mutations (Filamin) * DIAPH1 (Actin and microtubules) * ACTN1 (alpha actinin) * TPM4 (tropomyosin) * TUBB1 (beta tubulin) 7. Other Congenital thrombocytopenias 1. Familial platelet disorders and predisposition to AML (RUNX1) 2. X linked thrombocytopenia with dyserythropoiesis (GATA1) 3. Congenital amegakaryocytic thrombocytopenia (MPL) Exclusion Criteria 1. Diagnosis of von Willebrand Disease (Meeting the definition of vWD or low vWF per most recent international guidelines) 2. Diagnosis of Hemophilia A or Hemophilia B (Factor VIII or IX ≤ 40%) Glanzmann Thrombasthenia (GT) Module Inclusion Criteria 1. Participant has signed the informed consent/assent form 2. Participant has flow cytometry or aggregometry or genetics confirmed GT 3. Participant is willing to perform study procedures, including daily bleed tracking for 3 months and further if requested 4. Participants are 2 years or older at time of consent Exclusion Criteria None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bleeding disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease blood platelet disease connective tissue disorder hematologic disorder hemophilia hemophilia A hemophilia B hemorrhagic disease hereditary von Willebrand disease inherited bleeding disorder, platelet-type sickle cell disease thalassemia thrombophilia thrombotic disease vascular hemostatic disease von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding disorder Connective tissue disorder Factor ix deficiency Factor viii deficiency Hematologic disorder Hemophilia Platelet disorder Rare bleeding disorder Sickle cell disease Thalassemia Thrombophilia Thrombosis Von Willebrand diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    76 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akron Children's Hospital - Showers Center for Cancer & Blood Disorders

    RECRUITING

    Akron, Ohio, 44308, United States

  • American Thrombosis and Hemostasis Network

    RECRUITING

    Rochester, New York, 14626, United States

  • Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital

    RECRUITING

    Phoenix, Arizona, 85016, United States

  • Arkansas Center for Bleeding Disorders

    RECRUITING

    Little Rock, Arkansas, 72202, United States

  • Arnold Palmer Hospital for Children - The Haley Center for Children's Cancer and Blood Disorders

    NOT_YET_RECRUITING

    Orlando, Florida, 32806, United States

  • Bleeding and Clotting Disorders Institute

    RECRUITING

    Peoria, Illinois, 61664, United States

  • Central Michigan Children's Hospital of Michigan

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Children's Blood and Cancer Center of Central Texas

    RECRUITING

    Austin, Texas, 78723, United States

  • Children's Hospital of Kings Daughters

    RECRUITING

    Norfolk, Virginia, 23507, United States

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Children's Mercy Hospital - Kansas City

    RECRUITING

    Kansas City, Missouri, 64108, United States

  • Children's National Hemophilia Center

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

  • Childrens Hospital Los Angeles

    RECRUITING

    Los Angeles, California, 90027-6016, United States

  • Cincinnati Children's Hospital Medical Center, Hemophilia & Thrombosis Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

  • Comprehensive Bleeding Disorders Center at Emory University and Children's Healthcare of Atlanta

    RECRUITING

    Atlanta, Georgia, 30308, United States

  • Comprehensive Center for Bleeding Disorders

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Comprehensive Hemophilia Treatment Center, University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27517, United States

  • Connecticut Children's Medical Center

    RECRUITING

    Hartford, Connecticut, 06106, United States

  • Cure 4 The Kids Foundation

    RECRUITING

    Las Vegas, Nevada, 89135, United States

  • Dayton Children's Hemostasis and Thrombosis Center

    RECRUITING

    Dayton, Ohio, 45404, United States

  • Delaware Hemophilia Treatment Center

    RECRUITING

    Wilmington, Delaware, 19801, United States

  • East Carolina University Hemophilia Treatment Center

    RECRUITING

    Greenville, North Carolina, 27834, United States

  • Emory/Children's Health Care of Atlanta

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Georgetown University

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

  • Gulf States Hemophilia and Thrombophilia Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Hemophilia & Thrombosis Treatment Center at UC San Diego Health

    RECRUITING

    San Diego, California, 92121, United States

  • Hemophilia Center of Western Pennsylvania

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

  • Hemophilia Outreach Center Green Bay

    RECRUITING

    Green Bay, Wisconsin, 54311, United States

  • Hemostasis and Thrombosis Center of Nevada

    RECRUITING

    Reno, Nevada, 89509, United States

  • Henry Ford Health System Bleeding and Thrombosis Treatment Center

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Indiana Hemophilia and Thrombosis Center

    RECRUITING

    Indianapolis, Indiana, 46260, United States

  • Iowa Hemophilia and Thrombosis Center

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • Johns Hopkins All Children's Hospital

    RECRUITING

    St. Petersburg, Florida, 33701, United States

  • Johns Hopkins University Hemophilia Treatment Center

    RECRUITING

    Baltimore, Maryland, 21287, United States

  • Loma Linda Hemoglobinopathy and Inherited Bleeding Disorder Program

    RECRUITING

    San Bernardino, California, 92408, United States

  • Louisiana Center for Bleeding and Clotting Disorders, Tulane University

    RECRUITING

    New Orleans, Louisiana, 70112, United States

  • Maine Hemophilia and Thrombosis Center

    RECRUITING

    Scarborough, Maine, 04074, United States

  • Massachusetts General Hospital Comprehensive Hemophilia and Thrombosis Treatment Center

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • Mayo Comprehensive Hemophilia Center

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Memorial Health University Medical Center

    RECRUITING

    Savannah, Georgia, 31403, United States

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10461, United States

  • Nationwide Children's Hospital Columbus

    RECRUITING

    Columbus, Ohio, 43205, United States

  • Newark Beth Israel Medical Center - Hemophilia Center

    RECRUITING

    Newark, New Jersey, 07122, United States

  • North Texas Comprehensive Hemophilia Treatment Center

    RECRUITING

    Dallas, Texas, 75390, United States

  • North Texas Hemophilia and Thrombosis Program - Pediatric Program / Center for Cancer & Blood Disorders

    RECRUITING

    Dallas, Texas, 75235, United States

  • Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center

    RECRUITING

    Hyde Park, New York, 11040, United States

  • Northwest Ohio Hemophilia Treatment Center at the Toledo Hospital

    RECRUITING

    Toledo, Ohio, 43606, United States

  • Ohio State University Medical Center

    RECRUITING

    Columbus, Ohio, 43203, United States

  • Orthopaedic Institute for Children HTC

    RECRUITING

    Los Angeles, California, 90007, United States

  • Penn Comprehensive Hemophilia and Thrombophilia Program/Hospital of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Rady Children's Hospital San Diego

    RECRUITING

    San Diego, California, 92123, United States

  • Rhode Island Hospital Hemostasis and Thrombosis Center

    RECRUITING

    Providence, Rhode Island, 02903, United States

  • Rush University Medical Center

    RECRUITING

    Chicago, Illinois, 60612, United States

  • South Texas Comprehensive Hemophilia and Thrombophilia Treatment Center

    RECRUITING

    San Antonio, Texas, 78229, United States

  • St. Christopher's Hospital for Children

    RECRUITING

    Philadelphia, Pennsylvania, 19134, United States

  • St. Joseph's Hospital Center for Bleeding & Clotting Disorders

    RECRUITING

    Tampa, Florida, 33607, United States

  • St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

  • Texas Children's Hemophilia & Thrombosis Center/Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

  • The John Bouhasin Center for Children with Bleeding Disorders

    RECRUITING

    St Louis, Missouri, 63104, United States

  • UCSF Benioff Children's Hospital Oakland

    RECRUITING

    Oakland, California, 94610, United States

  • University Hospitals Health System Cleveland

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • University of California at Davis Hemophilia Treatment Center

    RECRUITING

    Sacramento, California, 95817, United States

  • University of California, San Francisco Hemophilia & Thrombosis Center

    RECRUITING

    San Francisco, California, 94143, United States

  • University of Cincinnati Medical Center Hemophilia Treatment Center

    RECRUITING

    Cincinnati, Ohio, 45267, United States

  • University of Florida Hemophilia Treatment Center

    RECRUITING

    Gainesville, Florida, 32610, United States

  • University of Miami Comprehensive Hemophilia Treatment Center

    RECRUITING

    Miami, Florida, 33136, United States

  • University of Miami Hospital and Clinics

    RECRUITING

    Miami, Florida, 33136, United States

  • University of New Mexico Ted R. Montoya Hemophilia & Thrombosis Program

    RECRUITING

    Albuquerque, New Mexico, 87131, United States

  • University of South Florida - Adult

    RECRUITING

    Tampa, Florida, 33612, United States

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37212, United States

  • Wake Forest University Health Sciences

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

  • Washington Center for Bleeding Disorders

    RECRUITING

    Seattle, Washington, 98101, United States

  • Weill Cornell Medical College - New York Presbyterian Hospital

    RECRUITING

    New York, New York, 10065, United States

  • Western New York BloodCare

    RECRUITING

    Buffalo, New York, 14202, United States

  • Yale Hemophilia Treatment Center

    RECRUITING

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.